Sergio Lombroso Award in Cancer Research presented to

May 24, 2001

Dr. Pier Paoli Pandolfi, of the Sloan-Kettering Institute, was presented with the Sergio Lombroso Award in Cancer Research. The award, administered by the Weizmann Institute of Science in Israel, is presented to a member of the international scientific or medical community who has made a significant contribution to the understanding of cancer and its treatment.

Dr. Pandolfi's research has been seminal in understanding and treating leukemia, lymphomas and solid tumors, as well as in modeling human cancers in mice and studying the therapeutic implications. Dr. Pandolfi earned both M.D. and Ph.D. degrees from the University of Perugia, Italy.

He received further post-graduate training at the National Institute for Medical Research and the University of London in the U.K. Dr. Pandolfi established his research laboratory at Memorial Sloan-Kettering Cancer Center in New York in 1994. He currently heads the Molecular and Developmental Biology Laboratories at MSKCC and serves as Associate Member and Professor at the Sloan-Kettering Institute and Cornell University.

Dr. Hanan Alon, Vice President of the Weizmann Institute of Science, presented the award in Washington, DC, during a program organized by the American Committee for the Weizmann Institute. Dr. Alon said that Dr. Paoli Pandolfi has made an important contribution to furthering the treatment of cancer. He described Dr. Pandolfi's passion for philosophy, in addition to science, and for helping humanity in a tangible way.

Mrs. Daniela Di-Segni, niece of the late Sergio Lombroso, for whom the Award is named, spoke about her uncle's commitment to help scientists battle cancer. She explained that it was Sergio Lombroso's love for Israel and respect for its achievements in science that led him to bequeath a gift to the Weizmann Institute of Science, a pioneer in the field of basic cancer research.

Speaking at the award ceremony, Dr. Pandolfi thanked the Lombroso family and the Weizmann Institute of Science for the award, which this year includes an $85,000 grant for his research at Sloan-Kettering and a $10,000 grant for use by the scientist. Dr. Pandolfi added that he plans to use part of the funding to develop joint research projects with scientists and graduate students from the Weizmann Institute.

Dr. Pandolfi dedicated his scientific presentation to the memory of his mother, who died of lung cancer, and expressed confidence that as research continues around the world, a cure for cancer will eventually be found.
-end-
The Weizmann Institute of Science, in Rehovot, Israel, is one of the world's foremost centers of scientific research and graduate study. Its 2,500 scientists, students, technicians and engineers pursue basic research in the quest for knowledge and to enhance the quality of human life. New ways of fighting disease and hunger, protecting the environment, and harnessing alternative sources of energy are high priorities at Weizmann.

American Committee for the Weizmann Institute of Science

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.